Sotera Health Appoints Kenneth D. Krause as Independent Director
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Sotera Health Company (SHC) has appointed Kenneth D. Krause as a new independent director to its Board of Directors. Mr. Krause has served as Executive Vice President and CFO of Rollins (ROL), since September 2022. On March 12, 2026, Constantine Mihas notified the Company that he will resign from the Board, effective March 16, 2026. His resignation is related to a reduction in the number of directors that certain stockholders are entitled to designate to the Board pursuant to the Company's Stockholders Agreement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SHC
Wall Street analysts forecast SHC stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 13.250
Low
16.00
Averages
20.42
High
24.00
Current: 13.250
Low
16.00
Averages
20.42
High
24.00
About SHC
Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company’s segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sessa Capital Acquires Additional Shares of Sotera Health
- Share Acquisition: On February 17, 2026, Sessa Capital disclosed the purchase of an additional 10,630,381 shares of Sotera Health, with an estimated transaction value of $175.80 million based on quarterly average pricing, indicating strong confidence in the company.
- Asset Management Impact: Following this transaction, Sessa Capital's quarter-end position value in Sotera Health rose to $206.47 million, reflecting the combined effects of trading activity and stock price movements, thereby reinforcing its position within the investment portfolio.
- Market Performance Comparison: As of Monday, Sotera Health shares were priced at $13.99, representing an 18% increase over the past year, slightly outperforming the S&P 500's approximately 15% gain, showcasing its relative strength in the market.
- Long-Term Growth Potential: With revenue reaching about $1.16 billion and adjusted EBITDA close to $600 million, Sotera Health has demonstrated a strong track record in healthcare services, and despite facing litigation and regulatory risks, its sustained growth potential continues to attract long-term investor interest.
See More
Sessa Capital Increases Stake in Sotera Health
- Share Increase: Sessa Capital added 10,630,381 shares of Sotera Health in Q4, with an estimated trade value of $175.80 million, reflecting confidence in the company's future growth prospects.
- Market Value Growth: By quarter-end, Sessa Capital's total holdings in Sotera Health reached 20,550,000 shares, valued at $362.50 million, showcasing the dual impact of stock price movement and share additions.
- Financial Performance: Sotera Health reported approximately $1.16 billion in revenue and nearly $600 million in adjusted EBITDA last year, demonstrating stable growth potential despite facing litigation and high leverage risks.
- Market Challenges: A recent secondary offering saw 25 million shares flood the market, creating technical pressure, which has affected investor confidence despite the company's strong fundamentals.
See More
Inherent Management Corp. Increases Stake in Sotera Health by $3.31 Million
- Share Acquisition: Inherent Management Corp. increased its stake in Sotera Health by 200,050 shares during Q4 2026, representing an estimated $3.31 million investment, indicating strong confidence in the company's future.
- Asset Allocation Shift: Following this acquisition, Sotera Health now constitutes 10.6% of Inherent's 13F assets under management, highlighting its significance within the portfolio, particularly in the healthcare services sector.
- Financial Performance: Sotera Health reported approximately 6% revenue growth over the past year, reaching $1.16 billion, and despite a 23% decline in share price, its fundamentals remain robust, showcasing the company's competitive position in the market.
- Market Sentiment: Although Sotera Health's shares rose 13% over the past year, investor concerns regarding litigation risks and regulatory scrutiny have led to a cautious market sentiment, prompting some investors to reduce their holdings.
See More
Inherent Management Corp. Increases Stake in Sotera Health
- Share Acquisition: Inherent Management Corp. purchased 200,050 shares of Sotera Health in Q4 2026, with an estimated trade value of $3.31 million, indicating strong confidence in the company.
- Value Appreciation: By quarter-end, the value of Sotera Health's position increased by $5.39 million, reflecting contributions from both the additional shares and the rise in the company's stock price, suggesting market recognition of its fundamentals.
- Consistent Growth: Sotera Health achieved its 20th consecutive year of revenue growth, with sales rising approximately 6% to $1.16 billion and adjusted EBITDA nearing $600 million, demonstrating its stability and growth potential in the healthcare sector.
- Market Sentiment Fluctuations: Despite solid fundamentals, Sotera Health's shares have declined about 23% since the end of the last quarter, primarily due to concerns over litigation exposure, leverage, and regulatory scrutiny, leading to a cautious investor sentiment.
See More
MIG Capital Reduces Stake in Sotera Health
- Share Reduction Details: MIG Capital sold 2,262,292 shares of Sotera Health in Q4 2025, with an estimated transaction value of $37.41 million, reflecting trading activities and share price fluctuations during the quarter.
- Position Value Decline: At the end of the quarter, the total position value in Sotera Health decreased by $31.83 million, indicating the impact of market conditions on the fund's portfolio, although the holding still represents nearly 6% of its assets.
- Company Performance: Sotera Health achieved a 5.7% sales growth in 2025, reaching $1.16 billion, while adjusted EBITDA rose 8.2% to approximately $594 million, demonstrating strong profitability in the healthcare and food safety sectors.
- Future Growth Outlook: Sotera Health projects revenue growth of 5% to 6.5% and adjusted EBITDA growth of 5.5% to 7% for 2026, suggesting that despite MIG Capital's reduction, there remains confidence in the company's future prospects.
See More
MIG Capital Reduces Stake in Sotera Health by 2.26 Million Shares
- Share Reduction Details: MIG Capital disclosed a reduction of 2,262,292 shares in Sotera Health during Q4 2025, with an estimated transaction value of $37.41 million, indicating a potential shift in confidence regarding the investment.
- Asset Management Impact: Following this sale, Sotera Health now represents 5.88% of MIG Capital's 13F assets, with the total position value declining by $31.83 million due to trading and price changes, highlighting the impact of market volatility on the portfolio.
- Company Performance: Sotera Health achieved a 5.7% revenue increase to $1.16 billion in 2025, while adjusted EBITDA rose by 8.2% to approximately $594 million, demonstrating strong profitability in the medical device and food safety sectors.
- Future Growth Outlook: Despite the reduction, Sotera Health projects revenue growth of 5% to 6.5% in 2026 and adjusted EBITDA growth of 5.5% to 7%, suggesting that MIG Capital still sees long-term potential in the company.
See More
Sessa Capital Acquires Additional Shares of Sotera Health
- Share Acquisition: On February 17, 2026, Sessa Capital disclosed the purchase of an additional 10,630,381 shares of Sotera Health, with an estimated transaction value of $175.80 million based on quarterly average pricing, indicating strong confidence in the company.
- Asset Management Impact: Following this transaction, Sessa Capital's quarter-end position value in Sotera Health rose to $206.47 million, reflecting the combined effects of trading activity and stock price movements, thereby reinforcing its position within the investment portfolio.
- Market Performance Comparison: As of Monday, Sotera Health shares were priced at $13.99, representing an 18% increase over the past year, slightly outperforming the S&P 500's approximately 15% gain, showcasing its relative strength in the market.
- Long-Term Growth Potential: With revenue reaching about $1.16 billion and adjusted EBITDA close to $600 million, Sotera Health has demonstrated a strong track record in healthcare services, and despite facing litigation and regulatory risks, its sustained growth potential continues to attract long-term investor interest.
See More
Sessa Capital Increases Stake in Sotera Health
- Share Increase: Sessa Capital added 10,630,381 shares of Sotera Health in Q4, with an estimated trade value of $175.80 million, reflecting confidence in the company's future growth prospects.
- Market Value Growth: By quarter-end, Sessa Capital's total holdings in Sotera Health reached 20,550,000 shares, valued at $362.50 million, showcasing the dual impact of stock price movement and share additions.
- Financial Performance: Sotera Health reported approximately $1.16 billion in revenue and nearly $600 million in adjusted EBITDA last year, demonstrating stable growth potential despite facing litigation and high leverage risks.
- Market Challenges: A recent secondary offering saw 25 million shares flood the market, creating technical pressure, which has affected investor confidence despite the company's strong fundamentals.
See More
Inherent Management Corp. Increases Stake in Sotera Health by $3.31 Million
- Share Acquisition: Inherent Management Corp. increased its stake in Sotera Health by 200,050 shares during Q4 2026, representing an estimated $3.31 million investment, indicating strong confidence in the company's future.
- Asset Allocation Shift: Following this acquisition, Sotera Health now constitutes 10.6% of Inherent's 13F assets under management, highlighting its significance within the portfolio, particularly in the healthcare services sector.
- Financial Performance: Sotera Health reported approximately 6% revenue growth over the past year, reaching $1.16 billion, and despite a 23% decline in share price, its fundamentals remain robust, showcasing the company's competitive position in the market.
- Market Sentiment: Although Sotera Health's shares rose 13% over the past year, investor concerns regarding litigation risks and regulatory scrutiny have led to a cautious market sentiment, prompting some investors to reduce their holdings.
See More
Inherent Management Corp. Increases Stake in Sotera Health
- Share Acquisition: Inherent Management Corp. purchased 200,050 shares of Sotera Health in Q4 2026, with an estimated trade value of $3.31 million, indicating strong confidence in the company.
- Value Appreciation: By quarter-end, the value of Sotera Health's position increased by $5.39 million, reflecting contributions from both the additional shares and the rise in the company's stock price, suggesting market recognition of its fundamentals.
- Consistent Growth: Sotera Health achieved its 20th consecutive year of revenue growth, with sales rising approximately 6% to $1.16 billion and adjusted EBITDA nearing $600 million, demonstrating its stability and growth potential in the healthcare sector.
- Market Sentiment Fluctuations: Despite solid fundamentals, Sotera Health's shares have declined about 23% since the end of the last quarter, primarily due to concerns over litigation exposure, leverage, and regulatory scrutiny, leading to a cautious investor sentiment.
See More
MIG Capital Reduces Stake in Sotera Health
- Share Reduction Details: MIG Capital sold 2,262,292 shares of Sotera Health in Q4 2025, with an estimated transaction value of $37.41 million, reflecting trading activities and share price fluctuations during the quarter.
- Position Value Decline: At the end of the quarter, the total position value in Sotera Health decreased by $31.83 million, indicating the impact of market conditions on the fund's portfolio, although the holding still represents nearly 6% of its assets.
- Company Performance: Sotera Health achieved a 5.7% sales growth in 2025, reaching $1.16 billion, while adjusted EBITDA rose 8.2% to approximately $594 million, demonstrating strong profitability in the healthcare and food safety sectors.
- Future Growth Outlook: Sotera Health projects revenue growth of 5% to 6.5% and adjusted EBITDA growth of 5.5% to 7% for 2026, suggesting that despite MIG Capital's reduction, there remains confidence in the company's future prospects.
See More
MIG Capital Reduces Stake in Sotera Health by 2.26 Million Shares
- Share Reduction Details: MIG Capital disclosed a reduction of 2,262,292 shares in Sotera Health during Q4 2025, with an estimated transaction value of $37.41 million, indicating a potential shift in confidence regarding the investment.
- Asset Management Impact: Following this sale, Sotera Health now represents 5.88% of MIG Capital's 13F assets, with the total position value declining by $31.83 million due to trading and price changes, highlighting the impact of market volatility on the portfolio.
- Company Performance: Sotera Health achieved a 5.7% revenue increase to $1.16 billion in 2025, while adjusted EBITDA rose by 8.2% to approximately $594 million, demonstrating strong profitability in the medical device and food safety sectors.
- Future Growth Outlook: Despite the reduction, Sotera Health projects revenue growth of 5% to 6.5% in 2026 and adjusted EBITDA growth of 5.5% to 7%, suggesting that MIG Capital still sees long-term potential in the company.
See More
